Additionally, we performed a CRISPR-Cas9 knock out of PTEN from the Myc-CaP genome, as concurrent MYC copy number gain and PTEN copy number loss is associated with prostate cancer-specific mortality and is reported in over half of deadly metastatic prostate tumors27. This evidence concerns the gene MYC and prostate carcinoma.